NRC
Nrc Health Health Care Services-Commercial Physical & Biological Research Russell 3000
$23.83Close
$539.4MMarket cap
$11.83 – $23.8352-week range
Jan 26, 2027Next report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 89 · stronger than 89% of stocks over 12 months
- Near its high at its 52-week high
Cautions
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 8.7%
price change
1mo
up 12.5%
price change
12-month return
up 87%
market up 11% ·
its own up 71%
F-score
—
— Not assessed
Altman Z″
0.03
Elevated risk
P/E
46.5×
price / earnings
PEG
—
P/E / EPS growth
P/B
38.6×
price / book
Earnings yield
up 3.7%
EBIT / enterprise value
Cheaper than
34%
of the market · expensive
Revenue growth
down 4%
year on year
EPS growth
—
latest quarter
Sales growth
up 4%
latest quarter · +0 pts
ROE
up 51%
return on equity
Free cash margin
up 11%
$15.7M FCF
D/E
5.36
long-term debt / equity
Net debt / EBITDA
2.3×
Interest cover
—EBIT / interest
Trade setup
ATR%
4.1%
$0.98 a day · 2×ATR $21.87
RS
89 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
1.35
50 sessions
Implied move
—
no scheduled report
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Revenue shrinking Revenue fell 4.0% over the year, from $143.1M to $137.4M.
Last reported
Oct 27, 2026
Last shock
Jul 29, 2026-18% in one session1.8× volumeon results+30% since
Financials
- Net 8%
- Free cash 11%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $133.3M | $148.0M | $151.6M | $148.6M | $143.1M | $137.4M |
| Operating income | $42.7M | $50.3M | $46.5M | $40.0M | $35.2M | $22.6M |
| Net income | $37.3M | $37.5M | $31.8M | $31.0M | $24.8M | $11.6M |
| Net margin | 28% | 25% | 21% | 21% | 17% | 8% |
| Earnings per share | $1.45 | $1.46 | $1.27 | $1.26 | $1.04 | $0.52 |
| Free cash flow | $36.7M | $40.8M | $26.4M | $22.3M | $19.2M | $15.7M |
| Free cash margin | 28% | 28% | 17% | 15% | 13% | 11% |
| Cash | $34.7M | $54.4M | $25.0M | $6.7M | $4.2M | $4.1M |
| Long-term debt | $26.5M | $26.6M | $22.3M | $29.5M | $57.9M | $75.0M |
| Shareholders' equity | $64.3M | $85.3M | $72.0M | $49.0M | $31.3M | $14.0M |
| Shares outstanding | 25.39m | 25.36m | 24.63m | 24.22m | 23.08m | 22.64m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Mar 5, 2026 | Annual ↗ | Dec 31, 2025 | 64d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Mar 17, 2025 | Annual ↗ | Dec 31, 2024 | 76d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 27, 2024 | Annual ↗ | Dec 31, 2023 | 58d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 27, 2026 | Results ↗ |
| Oct 19, 2026 | Director or officer change ↗ |
| Aug 11, 2026 | Director or officer change ↗ |
| Jul 28, 2026 | Results ↗ |
| Jun 29, 2026 | Charter or bylaws · Shareholder vote ↗ |
| Apr 28, 2026 | Director or officer change ↗ |
| Apr 28, 2026 | Results ↗ |
| Apr 20, 2026 | Director or officer change · Charter or bylaws ↗ |
| Mar 5, 2026 | Regulation FD ↗ |
| Feb 3, 2026 | Results ↗ |
| Oct 27, 2025 | Results ↗ |
| Aug 28, 2025 | Director or officer change ↗ |